welcome to STERNA BIOLOGICALS

Konstantin joined sterna as CEO in June 2023. In addition to his role at sterna, he also serves as CBO of Secarna Pharmaceuticals. Prior to this, he was CEO of AMW, a revenue-generating specialty pharmaceuticals company. Over the last 15 years, Konstantin has held senior management positions at several biotech and pharma companies including Bayer, MorphoSys and Leukocare.

Konstantin has a Ph.D. in oncology from the Ludwig-Maximilians-University, Munich, Germany and holds an MBA from the University of Applied Sciences for Economics and Management.

Daniel became CSO of sterna in July 2020. He has worked in pharmaceutical R&D with a focus on inflammatory diseases for more than 25 years. His expertise spans from early drug discovery to clinical proof of concept and beyond. He held R&D positions at Novartis and Revotar Biopharmaceuticals before working as an independent expert, advisor and consultant..

Daniel received a Ph.D. from the University of Hannover, Germany.

Nina joined sterna in January 2021 and has contributed significantly to the development of the Company’s programs. In September 2023, she was promoted to Chief Operating Officer.

Nina has more than 15 years of experience in the pharmaceutical industry, where she developed strong management skills. Prior to her time at sterna, Nina held several leading roles in R&D, program management and product development at Vectura GmbH and medac GmbH.

From 2007 to 2011, she worked at the German Cancer Research Center (DKFZ) in Heidelberg, Germany, where she also acquired a Ph.D. in Immunobiology.

Before joining sterna biologicals in 2022, Thomas served as Chief Financial Officer and deputy Chief Executive Officer at several publicly listed companies including MK AG and Medigene AG. Thomas was an Assistant Professor at the University of Mannheim in Germany and a Research Fellow at the M.I.T. Sloan School of Management in Boston, where his research focused on innovation management and organizational changes in industrial corporations.

Thomas holds a Ph.D. in Business Economics (Mannheim) and a M. Eng. (K.I.T.) and is a Harvard Business School graduate.